Mounjaro and Zepbound. Those drugs brought in a combined $4.4 billion in sales for Lilly in this year's third quarter. The drugmaker plans to start construction of the expansion next year.
Eli Lilly said on Wednesday patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy in the first large, head-to-head trial of the highly in ...
Eli Lilly said its obesity drug Zepbound led to more weight loss than its main rival, Novo Nordisk's Wegovy, in the first head-to-head clinical trial on the two weekly injections. The findings ...
Glass, MD, FACE, senior vice president of global medical affairs at Lilly Cardiometabolic Health. "We are thrilled that today's findings showed the superior weight loss of Zepbound, which helped ...
This translates to people on Zepbound losing roughly 50 pounds compared to 33 pounds on Wegovy during the 72-week trial. An Eli Lilly & Co. Zepbound injection pen in Brooklyn, N.Y, March 28 ...
Eli Lilly and Company announced topline results from the SURMOUNT-5 phase 3b open-label randomized clinical trial. Zepbound (tirzepatide) provided a 47% greater relative weight loss compared to Wegovy ...
Lilly's Zepbound shows 47% more weight loss than Wegovy in trial First study comparing the drugs under same trial parameters Novo to wait for full trial data, flags Wegovy's heart benefits The U.S ...
Participants using Zepbound lost 50.3 lbs (22.8 kg) and participants on Wegovy lost 33.1 lbs (15.0 kg) INDIANAPOLIS, Dec. 4, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback